Medicamentous treatment of chronic heart failure

Eyubova U, Azerbaijan Medical University, Azerbaijan

Abstract

Actuality: Heart failure has become a topical issue in world health recent years due to the high prevalence, rehospitalization, poor prognosis and mortality rate. As the principal pathophysiological mechanism of the progression of this pathology, the focus is on left-ventricular dysfunction, neurohumoral activity and ventricular remodelling. In recent years, numerous studies on the pathogenesis of the disease has revealed important advances in the treatment of the disease. One of them is the detailed study of the role of BNP in the pathogenesis of the disease and the use of therapies based on this.

Purpose: To study the effects of sacubitril/valsartan combination in patients with long-term chronic heart failure, whose left ventricular ejection fraction is below 40%.

Materials & methods: The results of 30 men and women suffering from long-term chronic heart failure with left ventricular ejection fraction below 40% were studied. Patients were over 25 years of age. Each patient was given a combination of sacubitril / valsartan 200 mg daily (100 mg in the morning and 100 mg in the evening). The patients were re-examined 6 months later with transtoracic echocardiography.

Results of study: An increase in the left ventricular ejection fraction in the majority of patients was observed post-transtoracic echocardiography after 6 months.

Summary: The study found a positive effect of adding the sacubitril / valsartan combination to the treatment of chronic heart failure in the majority of patients with the left ventricular ejection fraction

Keywords: Heart failure, Standards, Drug therapy, Angiotensin receptor-neprilysin inhibitor

INTRODUCTION: Congestive heart failure (HF) affects millions of patients around the world; due to an aging population, prevalence is expected to increase in the near future. HF is characterized by a very poor prognosis without therapy.[1)] HF-associated mortality is higher than most malignancies.[2]. Present day sedate medicines and the ensuing utilization of built up drug have considerably diminished mortality and hospitalization recurrence, in any event in patients with HF with decreased discharge division (HFrEF). Therefore, adjusting persistent treatments to current rules is basic for HF understanding administration. In 2016, the European Society of Cardiology (ESC) introduced their new and refreshed rules on the conclusion and treatment of HF.[3)] Simultaneously, a working gathering of delegates from the American Heart Association (AHA), the American College of Cardiology (ACC), and the Heart Failure Society of America (HFSA) distributed an update to the rules, which concentrated on the pharmacological administration of HF.[4)]

The major targets for HF treatment are as follow3): side effect improvement, useful limit improvement, upgrading personal satisfaction, lessening the recurrence of hospitalizations, and diminishing related mortality.

Remedial methodologies for HF contrast contingent upon its introduction. The two entrenched sorts are HF with diminished discharge division (HFrEF, left ventricular launch portion (LVEF) <40%) and HF with protected launch part (HFpEF; LVEF ≥50% and indications of diastolic brokenness). The new rules presented another type of HF, called HF with mid-extend launch portion (HFmrEF; LVEF 40%–49% and indications of diastolic dysfunction).[3] This expansion was acquainted with better characterize the symptomatic hazy area among HFpEF and HFrEF. A wide range of HF are described by diminished stroke volume and successively heart yield. There is no away from for the treatment of HFmrEF patients in the present rules because of missing examinations. Notwithstanding, there is proof that patients with HFmrEF may more probable profit by sedate treatment set up for HFrEF contrasted with patients with HFpEF.[5]

THERAPY FOR PATIENTS WITH HFrEF

The basic treatment strategy for HFrEF is neurohormonal inhibition by enzyme converting angiotensin (ACE) inhibitors (ACEIs), mineralocorticoid receptor antagonists (MRAs) and beta-blockers. This clinical theory has been shown to be applicable in a variety of randomized trials, leading to class IA recommendations in the existing guidelines.

ACE INHIBITORS (ACEI) AND ANGIOTENSIN-II BLOCKERS (ARB)

ACEIs obstruct the cleavage of angiotensin-I to angiotensin-II, subsequently repressing the notable impacts of angiotensin-II, which are summed up in Table 1. ACEIs have been utilized in clinical practice for a long time. Numerous preliminaries have indicated that they have gainful impacts, including diminished mortality and recurrence of hospitalizations, on HFrEF understanding guesses in a few clinical settings; for instance, the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) [6] and the Studies of Left Ventricular Dysfunction (SOLVD).[7] ACEI treatment in HFrEF is as of now a norm. As indicated by the ESC rules, each patient with HFrEF ought to get an ACEI, autonomous of their side effects.

Effects of angiotensin-II

Hemodynamic	Vasoconstriction (preferentially coronary, renal, cerebral)
	- Increase in peripheral vascular resistance
	- Increased afterload
	- Left ventricular hypertrophy
	Inotropic/contractile (cardiomyocytes; increased cytosolic Ca^{2+})
Neurohumoral	Renin-suppression (negative

	feedback)	proliferation
	Activation of the sympathetic nervous system	- Stimulation of vascular and myocardial fibrosis
	Aldosterone release (sodium retention)	Matrix deposition
	ADH release (water retention)	Prothrombotic/proatherogenic Platelet aggregation
	Increased endothelin secretion	Vascular smooth cell migration
Proliferative	Promotion of cell growth/growth factor stimulation	Increased synthesis of PAI-1
	- Cardiomyocyte hypertrophy	
	- Vascular smooth muscle cell	

Description was modified from several references.[10),35),36),37)]

ADH = antidiuretic hormone; PAI-1 = plasminogen activator inhibitor-1.

In the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial,[8)] a low-portion treatment with the ACEI Lisinopril was contrasted with a high-portion treatment in more than 3,000 patients with HFrEF. Patients in the high-portion bunch had essentially lower chance for hospitalization and mortality. To accomplish satisfactory restraint of the renin-angiotensin framework,

up-titration of the ACEI portion to the objective portion or the most extreme endured portion is suggested. This is particularly valid for more youthful patients in whom high dosages ought to be reached. By the by, all things considered, portions are regularly beneath the suggested level.[9)]

In patients who don't endure ACEIs, principally because of hack or angioedema, ARBs are an elective treatment. The mix of ACEIs and ARBs is just suggested in uncommon cases and is contraindicated in patients with accompanying MRA treatment.

BETA-BLOCKERS

One of the earliest neurohumoral changes in HF is sympathetic activation.10) Short-term sympathetic activation increases peripheral perfusion by increasing heart rate and myocardial contractility. Continuous activation deteriorates the function of the heart and these effects are shown in Table 2.

Table 2

Ongoing sympathetic activation adversely affecting cardiac myocyte and chamber contractile function leading to deterioration of heart function

Desensitization of signal transduction	Abnormal transduction of the beta-adrenergic signal
	- Reduced maximal functional capacity
	- Myocardial protection from adrenergic stimulation
Adverse biologic effects on cardiac myocytes	Alterations in gene expression leading to myocyte dysfunction
	- Reinduction of fetal genes
	- Myosin heavy chain isoform shifts
	Cell loss/acceleration of myocyte death
	- Necrosis (subendocardial ischemia, toxic effects)
	- Apoptosis
	Cell (myocyte) and chamber (left ventricular) remodeling
	- Myocardial hypertrophy
	- Fibroblast

	hyperplasia
	Induction of tachyarrhythmia
	Increase of heart rate/tachycardia
	- Subendocardial ischemia
	- Reduced diastolic filling time
	- Negative inotropic effect
	Altered myocardial metabolism
	- Increased free fatty acid uptake with decreased myocardial efficiency
	- Increased anaerobic glycolysis
	- Myofibril desensitization to calcium caused by intracellular acidosis
Others	Increased renin secretion

Description was modified from several references.[10),38),39),40)]

Different examinations have indicated the valuable impacts of a treatment with beta-blockers in HFrEF, including the Cardiac Insufficiency Bisoprolol Study II (CIBIS II),11) Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS),12) Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF),13) and the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS).14)

Like ACEIs, beta-blockers ought to be begun at a low-portion, and measurements ought to be expanded in the clinical course. Total contraindications are [1)] important bradycardia, [2)] second-or third-degree heart obstruct (without a pacemaker), and [3)] bronchial asthma. Interminable obstructive lung infection is normally no contraindication for beta-blocker treatment. As indicated by the current ESC rules, ACEIs and beta-blockers ought to be begun following conclusion of HFrEF.[3)]

MINERALOCORTICOID RECEPTOR ANTAGONISTS (MRA), FORMERLY ALDOSTERONE ANTAGONISTS

Regulation of aldosterone synthesis is regulated by angiotensin-II and by plasma potassium. Activation of the mineralocorticoid receptor, which can also be activated by glucocorticoids, leads to several effects that

can worsen cardiac function. An overview is given in Table 3.

Table 3
(Deleterious) Effects of the activation of the mineralocorticoid receptor

Sodium reabsorption and volume overload	Decrease in cardiac output
	Reduced renal flow
	- RAAS stimulation in the kidneys
	Increase in urinary potassium excretion
	- Hypokalemia
	- Electrical instability
	Hypertension
Ventricular remodeling	Myocardial hypertrophy
	Increased inflammation and upregulated expression of proinflammatory cytokines (TNF-α, IL-1β, TGF-β)
	Increased collagen synthesis by cardiac fibroblasts
	- Fibrosis of the perivascular and interstitial spaces
	- Increased ventricular diastolic stiffness
	- Electrical conduction defects
	- Malignant ventricular arrhythmia
Endothelial dysfunction and vasoconstriction	Reduced coronary blood flow
	- Recurrent ischemic events

- Myocardial ischemia

- Myocardial injury

Description was modified from several references.[10),41),42)]

IL-1β = interleukin-1β; RAAS = renin-angiotensin-aldosterone system; TGF-β = transforming growth factor-β; TNF-α = tumor necrosis factor-α.

After the Randomized Aldactone Evaluation Study (RALES)15) and Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS),16) MRA treatment for patients with HFrEF and extreme side effects (New York Heart Association [NYHA] class III and IV) has been set up and executed in the rules.
In the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) preliminary Zannad et al.17) demonstrated that patients with HFrEF and milder manifestations (NYHA class II) may profit by a treatment with a MRA notwithstanding the suggested and set up tranquilize treatment. The composite endpoint (cardiovascular mortality and hospitalization for HF) was huge lower (37%) in the eplerenone bunch in contrast with the fake treatment gathering. Moreover, all-cause mortality (24%), cardiovascular demise (24%), all-cause hospitalizations (23%), and HF hospitalizations (42%) were all altogether decreased. The aftereffects of the EMPHASIS-HF preliminary have prompted the suggestion that all patients with diminished left ventricular capacity (LVEF ≤35%) and persevering indications (NYHA class II–IV) regardless of treatment with an ACEI (then again ARB) and a beta-blocker ought to get a MRA except if there are contraindications.3)

The most significant antagonistic impact of a treatment with MRA is hyperkalemia. Along these lines, the treatment approaches ought to be utilized with alert in patients with existing hyperkalemia (>5.0 mmol/L) and in patients with seriously disabled renal capacity (creatinine leeway <30 mL/min). Renal markers and electrolytes ought to be checked consistently in older patients, particularly those with corresponding prescriptions, for example, an ACEI or an ARB. In any case, examines have exhibited that more seasoned patients (≥75 years) and patients with modestly disabled renal capacity profit by treatment with eplerenone.17),18)

Notwithstanding the set up MRAs spironolactone and eplerenone, another medication, finerenone, has been presented and has a non-steroidal structure. Because of this diverse structure, finerenone treatment may be related with less antagonistic effects;19) nonetheless, consequences of progressing contemplates have not yet been distributed.

DIURETICS

The impacts of diuretics on mortality and dreariness have not been concentrated in randomized preliminaries. By the by, in patients with indicative HF (NYHA class II–IV), diuretics ought to be added to the medication treatment referenced above so as to enhance a portion of the side effects (for example dyspnea, edema).3) The portion of diuretics ought to be as low as conceivable to reach and keep up euvolemia. Over the span of the sickness, achievable portion decreases ought to be checked routinely.

If-CHANNEL INHIBITOR

Ivabradine focuses on the sinu-atrial hub and eases back the sinus mood through If-channel restraint. Patients with HFrEF (NYHA class II–IV, LVEF ≤35%) and in sinus mood (pulse ≥70 bpm) were taken a crack at the Systolic Heart Failure Treatment with If Inhibitor Ivabradine Trial (SHIFT). The organization of ivabradine notwithstanding an advanced HF prescription (counting beta-blocker) brought about a critical lessening in HF hospitalizations and cardiovascular mortality (essential endpoint, relative hazard decrease 18%).20) Furthermore, left ventricular capacity was upgraded and personal satisfaction improved. Because of the consequences of the SHIFT preliminary, ivabradine is suggested in patients with HFrEF (LVEF ≤35%), sinus mood with a pulse ≥70

bpm, and continuing side effects regardless of treatment with an ACEI (or ARB), a beta-blocker, and a MRA.3)

In Europe, the authority naming for ivabradine to treat HF is for patients in sinus cadence with a pulse ≥75 bpm. These patients have been appeared to eminently profit by this treatment since a subgroup investigation found a critical decrease of mortality in this cohort.21)

ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR (ARNI)

Another medication class has as of late rose in HF treatment. ARNI is a novel treatment idea in HF. The first and to this date just substance in this class is "LCZ696," which is included an ARB (valsartan) and sacubitril, a nonpartisan endopeptidase (NEP, neprilysin) inhibitor. Neprilysin assumes a vital job in the debasement of natriuretic peptides. The restorative idea of the ARNI depends on the built up hindrance of the renin-angiotensin-aldosterone framework (RAAS) and an expansion in endogenous natriuretic peptides by hindering their debasement. Restraint of neprilysin balances the neurohumoral actuation, which prompts vasoconstriction, sodium maintenance, and cardiovascular rebuilding, expanding the RAAS-blocking effects.22)

The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) preliminary was an enormous randomized stage III examination to explore the useful impacts of this new helpful concept.23) An aggregate of 8,442 HFrEF patients were taken on a wandering setting. Significant incorporation models were 1) indicative HF (NYHA class II–IV), 2) decreased left ventricular capacity (LVEF ≤40%, changed to ≤35% over the span of the investigation), 3) mind natriuretic peptide (BNP) ≥150 pg/mL or N-terminal proBNP (NT-proBNP) ≥600 pg/mL (≥100 separately 400 pg/mL with a HF hospitalization in the past a year), and 4) an expected glomerular filtration rate ≥ 30 mL/min/1.73 m2). Treatment with sacubitril/valsartan (target portion: 400 mg/day, equal to 320 mg valsartan+80 mg sacubitril) was contrasted with a treatment with the ACEI enalapril (target portion: 20 mg/day).

The essential endpoint, made out of cardiovascular mortality and HF hospitalizations, was fundamentally diminished in the sacubitril/valsartan gathering (20%). Moreover, critical decrease was appeared for cardiovascular mortality (20%), all-cause mortality (16%), and HF hospitalization (21%). Endpoint information and antagonistic occasions are portrayed in Figure 1.



Figure 1

Fundamental outcomes including study endpoints and unfriendly occasions, of the PARADIGM-HF preliminary, looking at the ARNI sacubitril/valsartan to the ACEI enalapril (adjusted from23))

ACEI = angiotensin changing over catalyst inhibitor; ARNI: angiotensin receptor-neprilysin inhibitor; PARADIGM-HF = Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure.

Because of the unmistakable impacts, treatment with sacubitril/valsartan is really suggested in the present rules for all patients

who meet the consideration standards and who stay indicative in spite of treatment with an ACEI (or ARB), a beta-blocker, and a MRA.3),4) When transforming from an ACEI to sacubitril/valsartan, admission of the ACEI must be halted at any rate 36 hours before the primary admission of sacubitril/valsartan so as to forestall angioedema.

As to security, the altogether higher rate of indicative hypotension under treatment with sacubitril/valsartan is critical to note. Subsequently, patients with extremely low circulatory strain during ACEI treatment ought not be changed to ARNI.24) Regarding sacubitril/valsartan treatment in patients with diabetes mellitus, an ongoing subgroup investigation found a predominance of sacubitril/valsartan contrasted and enalapril free from the patient's glycemic status (normoglycemic, pre-diabetes, diabetes).25)

DIGITALIS

The job and importance of cardiovascular glycosides in constant HF treatment are as of now muddled. One forthcoming randomized examination with digoxin (Digitalis Investigation Group [DIG] preliminary) in patients with HFrEF (LVEF ≤45%, NYHA class I–IV, sinus mood) has been performed.26) The DIG preliminary was led preceding the execution of the present HF medicine; in this manner, the pace of patients getting corresponding treatment with beta-blockers and MRA was exceptionally low. The investigation was deciphered as unbiased in light of the fact that digoxin didn't impact absolute mortality, which was characterized as the essential endpoint in this examination, despite the fact that hospitalizations for HF were diminished altogether. An as of late distributed subgroup examination of the DIG preliminary had the option to show that patients with low serum levels of digoxin (0.5–0.9 ng/mL) profited by this therapy.27) Total mortality in this subgroup was essentially decreased, though patients with high serum levels of digoxin displayed higher mortality levels. By and large, there is proof that improvement in anticipation in patients with HF that got digoxin isn't identified with its inotropic impact however to a useful neurohumoral balance. Particularly patients with cutting edge HF (NYHA III–IV, LVEF <25%) appear to profit by the helpful utilization of heart glycosides as to mortality and hospitalization rates.28) Reports on expanded mortality through cardiovascular glycosides in HF are constrained by their review and non-randomized plan and in this way, best case scenario theory generating.29)

In patients with HF and atrial fibrillation (AF), randomized examinations have not yet been performed to evaluate the effect of digoxin, and there are right now no randomized preliminaries on the cardiovascular glycoside digitoxin in HF or potentially AF. A huge randomized examination researching the job of digitoxin in patients with HF on contemporary medication treatment is in progress: the Digitoxin to Improve Outcomes in Patients with Advanced Systolic Chronic Heart Failure (DIGIT-HF) preliminary (EudraCT-Nr.: 2013-005326-38).

Because of the limited remedial scope of cardiovascular glycosides, they ought to be utilized with alert, particularly in ladies, more seasoned patients, and patients with disabled renal function.3) Digitoxin ought to be utilized for patients with weakened renal capacity, as opposed to digoxin, as digoxin is discharged primarily by the kidneys.

TREATMENT OF PATIENTS WITH HFpEF

Until this point, no randomized preliminary has shown the advantage of any medication treatment on mortality in patients with HFpEF.3) Therefore, the essential helpful objective in those patients is to improve side effects (for example edema, dyspnea) and emotional prosperity. A satisfactorily dosed treatment with diuretics is prescribed to arrive at this objective. In this setting note that the reasons for hospitalization and mortality in HFpEF patients are as often as possible non-cardiovascular. Screening for comorbidities and enough rewarding the comorbidities are significant suggestions of the genuine rules.

Additionally, patients in sinus musicality profit by treatment with nebivolol, spironolactone, or candesartan, which have been appeared to decrease HF hospitalizations.3) Similar outcomes have not been distributed in patients with AF. Besides,

adequate administration of circulatory strain, ideally with renin-angiotensin framework inhibitors, sufficient treatment of myocardial ischemia, and worthy pulse control in patients with AF are significant treatment focuses in patients with HFpEF. The last is entangled by the way that no examinations exist that characterize the ideal objective pulse or favored pharmacological substances (beta-blocker, digitalis, calcium channel blockers [CCB]) for HFpEF patients.3)

CONTRAINDICATED MEDICATION IN HF

Some treatments, which are known to cause harm in HF patients, should not be used, according to the ESC guidelines. An overview of these contraindicated drugs is given in Table 4.

Table 4

Overview of contraindicated drugs in HF patients

Substance	Potential effects
Thiazolidinediones (glitazones)	Worsening of HF
CCB (excluding amlodipine and felodipine)	Negative inotropic effect
	Worsening of HF
	Increase in hospitalizations
NSAID, COX-2 inhibitors	Sodium and water retention
	Worsening of kidney function
	Worsening of HF
	Increase in hospitalizations
Adding an ARB to an ACEI and a MRA	Possible worsening of kidney function
	Increased risk of hyperkalemia
Dronedarone (for control of frequency and rhythm in AF)	Increased risk of cardiovascular events
	Increased mortality

Substance	Potential effects
Class I antiarrhythmic agents	Increased mortality
Combination of ivabradin, ranolazine, and nicorandil	Unclear safety
Combination of nicorandil and nitrates	Missing additional effect
Moxonidin	Increased mortality
Alpha blockers	Neuro-humoral activation
	Water retention
	Worsening of HF

Description was modified from reference.3)

ACEI = angiotensin changing over protein inhibitor; AF = atrial fibrillation; ARB = angiotensin-II receptor blocker; CCB = calcium channel blocker; COX-2 = cyclooxygenase-2; HF = cardiovascular breakdown; MRA = mineralocorticoid receptor adversary; NSAID = non-steroidal mitigating drugs.

CO-MORBIDITIES IN HF

As of late, HF persistent comorbidities have gotten expanded consideration. Diagnostics and treatment of those co-morbidities collaborate with diagnostics and treatment of HF. Besides, they often hinder anticipation and disturb HF manifestations. With respect to treatment, two significant co-morbidities ought to be referenced.

Diabetes

Dysglycemia and diabetes are extremely normal in HF, and concurrence of diabetes disables the guess in HF. Metformin is the treatment of decision in patients with HF, at whatever point it isn't contraindicated (for example seriously weakened liver or kidney function).3) Glitazones are contraindicated in HF as they incite sodium and liquid maintenance and exacerbate HF.

Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor (Figure 2A). As of late, treatment with empagliflozin has been related with decreased hospitalization recurrence for HF and by and large mortality in an associate of patients with diabetes.30) The principle aftereffects of the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG) are appeared in Figure 2B. A subgroup investigation uncovered comparative outcomes for patients with prior HF;31) subsequently, empagliflozin is a promising substance in HF and associative diabetes.



Figure 2
(A) Mode of action of empagliflozin, a SGLT2 inhibitor, in the kidneys. (B) The main results of the EMPA-REG trial on cardiovascular outcomes in patients with type 2 diabetes (adapted from30)).

EMPA-REG = Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients; HF = heart failure; n.s. = not significant; SGLT2 = sodium-glucose cotransporter-2.

*Death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, †Excluding fatal stroke, ‡p value for test of superiority.

Iron deficiency

Iron insufficiency causes brokenness of significant proteins in the heart muscle and prompts frailty. Iron lack debilitates guess in HFrEF, whether or not the patient has anemia.3),32) In the Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency (FAIR-HF) trial,33) intravenous organization of iron (ferric carboxymaltose) essentially improved exercise limit and personal satisfaction in patients with HF (LVEF ≤40% and NYHA class II–III or LVEF ≤45% and NYHA class III) and demonstrated iron inadequacy (ferritin <100 mg/L or ferritin 100–299 µg/L and transferrin immersion <20%). The impact was autonomous of attendant anemia.33) In an ongoing meta-investigation, intravenous iron replacement was demonstrated to be related with a lower danger of hospitalizations in HF patients.34) In the present rules, intravenous iron treatment is suggested in all HF patients with affirmed iron deficiency.3)

CONCLUSION

Congestive HF is a developing issue because of the expanding pervasiveness; HF guess without treatment is horrible. Remedial advances have improved the forecast as of late; in this manner, fitting medication treatment in satisfactory portions - as suggested in the present rules - is urgent for HF patients.

Notwithstanding the built up tranquilize treatment comprising of ACEI (or ARB), betablocker, and diuretics, treatment with MRA and ivabradine have gotten standard in suggestive patients with HFrEF. The ARNI sacubitril/valsartan is a promising new expansion to current pharmacological medicines. The consequences of the PARADIGM-HF preliminary have been articulated to such an extent that they have prompted a class IB proposal by the ESC for indicative patients notwithstanding the 'work of art' HF drug.

Determination and treatment of comorbidities are developing worries in HF patients. In any case, in HFpEF no treatment has demonstrated

critical improvement as far as anticipation in any preliminary. In this way, treatment of comorbidities is a significant methodology for HFpEF patients, and extra research will be required.

References

1. Heart Failure Society of America HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16:e1–e194.

2. Askoxylakis V, Thieke C, Pleger ST, et al. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer. 2010;10:105.

3. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.

4. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68:1476–1488.

5. Solomon SD, Claggett B, Lewis EF, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37:455–462

6. CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N Engl J Med. 1987;316:1429–1435.

7. SOLVD Investigators Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302

8. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312–2318.

9. Maggioni AP, Anker SD, Dahlström U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15:1173–1184.

10. Heart Failure: 150 Questions & Answers. 2nd ed. Neuilly-sur-Seinex: Servier; 2011.

11. CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13.

12. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194–2199.

13. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283:1295–1302.

14. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur Heart J. 2005;26:215–225.

15. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717.

16. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321.

17. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.

18. Eschalier R, McMurray JJ, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure) J Am Coll Cardiol. 2013;62:1585–1593

19. Bauersachs J. The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects? Eur Heart J. 2013;34:2426–2428.

20. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–885.

21. Böhm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102:11–22.

22. Berliner D, Bauersachs J. Eine vielversprechende neue Behandlungsoption - verändert LCZ696 die Therapie der Herzinsuffizienz? Kompendium Herz-Kreislauf. 2015;11:23–27.

23. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.

24. Dec GW. LCZ696 (sacubitril/valsartan): can we predict who will benefit? J Am Coll Cardiol. 2015;66:2072–2074.

25. Kristensen SL, Preiss D, Jhund PS, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail. 2016;9:e002560.

26. Digitalis Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–533.

27. Adams KF, Jr, Butler J, Patterson JH, et al. Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. Eur J Heart Fail. 2016;18:1072–1081.

28. Gheorghiade M, Patel K, Filippatos G, et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013;15:551–559.

29. Bavendiek U, Aguirre Davila L, Koch A, Bauersachs J. Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure. Eur Heart J. 2017 [Epub ahead of print]

30. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and

mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.

31. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37:1526–1534.

32. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31:1872–1880.

33. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436–2448.

34. Jankowska EA, Tkaczyszyn M, Suchocki T, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail. 2016;18:786–795.

35. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637–645.

36. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103:904–912.

37. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:1208–1219.

38. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997;80:26L–40L.

39. Metra M, Nodari S, D'Aloia A, Bontempi L, Boldi E, Cas LD. A rationale for the use of β-blockers as standard treatment for heart failure. Am Heart J. 2000;139:511–521.

40. Bristow MR. Why does the myocardium fail? Insights from basic science. Lancet. 1998;352(Suppl 1):SI8–SI14.

41. Young MJ, Lam EY, Rickard AJ. Mineralocorticoid receptor activation and cardiac fibrosis. Clin Sci (Lond) 2007;112:467–475.

42. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65:257–263.

Note: This work is partly presented at 31st European Heart and Heart Failure Congress June on 18-19, 2020 held at Paris, France